Active, not recruitingPhase 1NCT06064929
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
Studying Systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- HI-Bio, A Biogen Company
- Principal Investigator
- Medical DirectorHI-Bio, A Biogen Company
- Intervention
- Felzartamab(drug)
- Enrollment
- 14 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2023 – 2026
Study locations (24)
- University of California, San Diego (UCSD), La Jolla, California, United States
- University of California, San Francisco (UCSF), San Francisco, California, United States
- Stanford University Medical Center, Stanford, California, United States
- ClinCept, LLC/River City Vascular Specialists LLC, Columbus, Georgia, United States
- Georgia Nephrology - Lawrenceville, Lawrenceville, Georgia, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Joseph S. and Diane H. Steinberg Ambulatory Care Center, Brooklyn, New York, United States
- SUNY Downstate Medical Center, Brooklyn, New York, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- The Ohio State University (OSU), Columbus, Ohio, United States
- Precision Comprehensive Clinical Research Solutions - Grapevine, Grapevine, Texas, United States
- Prolato Clinical Research Center, Houston, Texas, United States
- Accurate Clinical Research - Katy, Katy, Texas, United States
- R & H Clinical Research, Katy, Texas, United States
- Hospital Britanico de Buenos Aires, Caba, Buenos Aires F.D., Argentina
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06064929 on ClinicalTrials.govOther trials for Systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07107659Safety and Efficacy of ONT01 in LupusHospital for Special Surgery, New York
- RECRUITINGNANCT07558850Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune DiseasesThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNCT06948110Deciphering the Genetic Architecture of Autoimmune DiseasesNational Human Genome Research Institute (NHGRI)
- RECRUITINGPHASE2NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Boehringer Ingelheim
- RECRUITINGPHASE3NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseEMD Serono Research & Development Institute, Inc.
- RECRUITINGEARLY PHASE1NCT07526350MTS109 in Patients With Refractory Autoimmune DiseasesShanghai Changzheng Hospital
- RECRUITINGEARLY PHASE1NCT07490041Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic DiseasesThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNANCT07470151Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology